Stemline Therapeutics (STML) 10-Q 12 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 08, 2013
Document and Entity Information	'	'
Entity Registrant Name	'STEMLINE THERAPEUTICS INC	'
Entity Central Index Key	'0001264587	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Non-accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	12,906,063
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Balance_Sheets

Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$87,667,229	$2,025,338
Prepaid expenses and other current assets	972,182	299,089
Total current assets	88,639,411	2,324,427
Furniture and fixtures, net	421,667	'
Deferred financing fees	'	2,705,184
Total assets	89,061,078	5,029,611
Current liabilities:	'	'
Accounts payable and accrued expenses	2,851,253	5,500,735
Total current liabilities	2,851,253	5,500,735
Convertible notes	'	2,006,881
Put option liability	'	30,415
Total liabilities	2,851,253	7,538,031
Stockholders' equity:	'	'
Preferred stock $0.0001 par value, 5,000,000 shares authorized, none issued and outstanding at December 31, 2012 and September 30, 2013	'	'
Common stock $0.0001 par value, 33,750,000 shares authorized at September 30, 2013 and 22,500,000 shares authorized at December 31, 2012, 12,886,983 shares issued and outstanding at September 30, 2013 and 3,476,501 shares issued and outstanding at December 31, 2012	1,289	347
Additional paid-in capital	109,907,599	4,660,488
Accumulated deficit during the development stage	-23,699,063	-7,169,255
Total stockholders' equity/(deficit)	86,209,825	-2,508,420
Total liabilities and stockholders' equity/(deficit)	$89,061,078	$5,029,611

Balance_Sheets_Parenthetical

Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Balance Sheets	'	'
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	33,750,000	22,500,000
Common stock, shares issued	12,886,983	3,476,501
Common stock, shares outstanding	12,886,983	3,476,501

Statements_of_Operations

Statements of Operations (USD $)	3 Months Ended		9 Months Ended		122 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating expenses:	'	'	'	'	'
Research and development	$3,323,662	$1,221,290	$10,569,909	$2,834,630	$22,015,577
General and administrative	2,253,652	946,321	5,492,545	2,318,473	14,977,341
Total operating expenses	5,577,314	2,167,611	16,062,454	5,153,103	36,992,918
Loss from operations	-5,577,314	-2,167,611	-16,062,454	-5,153,103	-36,992,918
Other income	'	265,218	30,649	277,678	966,167
Other expense	'	'	'	-35	-9,705
Interest expense	'	-29,207	-505,037	-79,245	-801,987
Interest income	3,790	2,025	7,034	9,907	967,617
Net loss from operations	-5,573,524	-1,929,575	-16,529,808	-4,944,798	-35,870,826
Less accretion of preferred stock dividends	'	'	'	'	-2,591,165
Add discount on redemption of preferred stock	'	'	'	'	12,171,765
Net loss attributable to common stockholders	($5,573,524)	($1,929,575)	($16,529,808)	($4,944,798)	($26,290,226)
Net loss attributable to common stockholders per common share:	'	'	'	'	'
Basic and Diluted (in dollars per share)	($0.45)	($0.56)	($1.74)	($1.44)	'
Weighted-average shares outstanding:	'	'	'	'	'
Basic and Diluted (in shares)	12,471,472	3,441,995	9,520,179	3,441,995	'

Statements_of_Cash_Flows

Statements of Cash Flows (USD $)	9 Months Ended		122 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities	'	'	'
Net loss	($16,529,808)	($4,944,798)	($35,870,826)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	38,333	'	38,333
Stock-based compensation expense	3,927,375	338,300	6,127,042
Non-cash interest expense	82,389	79,245	379,339
Mark to market of put option liability	-30,415	-45,960	-111,420
Beneficial conversion of convertible notes	422,648	'	422,648
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other current assets	-673,093	-82,097	-972,182
Accounts payable and accrued expenses	55,702	1,613,432	2,851,253
Net cash used in operating activities	-12,706,869	-3,041,878	-27,135,813
Cash flows from investing activities	'	'	'
Purchase of furniture and fixtures	-460,000	'	-460,000
Purchase of marketable securities	'	'	-20,545,087
Redemption of marketable securities	'	'	20,545,087
Net cash used in investing activities	-460,000	'	-460,000
Cash flows from financing activities	'	'	'
Proceeds from issuance of preferred stock, net	'	'	12,500,000
Redemption of preferred stock	'	'	-750,000
Proceeds from issuance of common stock, net	97,708,506	'	101,550,788
Proceeds from exercise of stock options	1,100,254	'	1,100,254
Proceeds from issuance of convertible notes	'	322,000	862,000
Net cash provided by financing activities	98,808,760	322,000	115,263,042
Net increase (decrease) in cash and cash equivalents	85,641,891	-2,719,878	87,667,229
Cash and cash equivalents at beginning of period	2,025,338	5,829,886	'
Cash and cash equivalents at end of period	87,667,229	3,110,008	87,667,229
Supplemental disclosure of non-cash transactions	'	'	'
Discount on redemption of preferred stock	'	'	12,921,765
Issuance of common stock on redemption of preferred stock	'	'	1,200,000
Accretion of preferred stock dividend	'	'	$2,591,165

Organization_and_Basis_of_Pres

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Organization and Basis of Presentation	'
Organization and Basis of Presentation	'
	1. Organization and Basis of Presentation
	Organization
	Stemline Therapeutics, Inc. (the “Company”) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells (“CSCs”) and tumor bulk. The Company’s activities to date have primarily consisted of advancing its two clinical stage programs, expanding and strengthening its intellectual property portfolio, developing its proprietary drug discovery platform, identifying and acquiring additional product and technology rights and raising capital. Accordingly, the Company is considered to be in the development stage as defined in Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 915, Development Stage Entities. The Company was incorporated in Delaware on August 8, 2003 (“Inception”) and has its principal office in New York, New York.
	Basis of Presentation
	The accompanying unaudited financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements include all adjustments (including normal recurring accruals) considered necessary for fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. Operating results for the current interim period are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2013 or any future periods.  This Form 10-Q should be read in conjunction with the audited financial statements and accompanying notes in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 (the “2012 Form 10-K”).   The Company believes that its existing cash, cash equivalents and marketable securities will be sufficient to cover its cash flow requirements for at least several years.
	Initial Public Offering
	On January 31, 2013, the Company completed its initial public offering (the “IPO”), selling 3,317,644 shares at an offering price of $10.00 per share. On January 29, 2013, the underwriters exercised in full their over-allotment option to purchase an additional 497,647 shares at an offering price of $10.00 per share. Aggregate gross proceeds from the IPO, including the exercise of the over-allotment option, were $38.2 million and net proceeds received after underwriting fees and offering expenses were approximately $32.3 million. Additionally, upon the closing of the IPO, certain transactions were triggered based on a successful completion of an IPO.  Convertible debt of $1.4 million principal, plus accrued interest thereon, was converted into 166,769 shares of common stock. The Company recorded approximately $1.5 million of compensation expense related to certain bonuses and salary increases payable upon continued employment and the occurrence of a specified financing, including the consummation of an initial public offering. Finally, the Company recorded one-time compensation expense of approximately $1.4 million for certain options and restricted stock that fully vested upon the closing of the IPO.
	Secondary Public Offering
	On May 16, 2013, the Company completed a follow-on public offering (the “Secondary Offering”), selling 4,137,931 shares at an offering price of $14.50 per share. On May 22, 2013, the underwriters exercised in full their over-allotment option to purchase an additional 620,689 shares at an offering price of $14.50 per share. Aggregate gross proceeds from the Secondary Offering, including the exercise of the over-allotment option, were $69.0 million, and net proceeds received after underwriting fees and offering expenses were approximately $64.5 million.
	Recently Adopted Accounting Policy
	In May 2011, the Financial Accounting Standards Board issued guidance that changed the requirement for presenting “Comprehensive Income” in the financial statements.  The update requires an entity to present the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements.  The Company adopted this pronouncement and elected to present a separate statement of comprehensive income.  The Company did not incur any components of comprehensive income for the periods presented and therefore did not include a statement of comprehensive income in the financial statements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	The Company’s significant accounting policies are described in more detail in the notes to the financial statements as set forth in the 2012 Form 10-K. However, the Company believes that the following accounting policies are the most critical to aid in fully understanding and evaluating its financial condition and results of operations.
	Furniture and Fixtures
	Furniture and fixtures are stated at cost, less accumulated depreciation. Depreciation is provided over the estimated useful lives of the respective assets, which is three years, using the straight-line method.
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents. The Company invests its excess cash principally in a 100% U.S. Treasury Money Market Fund and the remaining balances in a major U.S. bank, and its deposits, at times, exceed federally insured limits. The Company has not experienced any losses from credit risks.
	Stock-Based Compensation
	The Company follows the provisions of the ASC Topic 718, Compensation — Stock Compensation which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees and non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is generally recognized as an expense over the requisite service period.
	The Company elected to recognize compensation cost using the straight-line attribution method for all service-based stock options.  For performance-based stock options share based compensation expense is recorded using the accelerated attribution method.
	For stock options granted as consideration for services rendered by non-employees, the Company recognizes expense in accordance with the requirements of ASC Topic 505-50, Equity Based Payments to Non-Employees. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the stock options are fully vested.
	Prior to becoming a public company, the board of directors determined the estimated fair value of the Company’s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of its common stock.
	Due to the lack of trading history, the Company’s computation of stock-price volatility is based on the volatility rates of comparable publicly held companies over a period equal to the estimated useful life of the options granted by the Company. The Company’s computation of expected life was determined using the “simplified” method which is the midpoint between the vesting date and the end of the contractual term. The Company believes that it does not have sufficient reliable exercise data in order to justify the use of a method other than the “simplified” method of estimating the expected exercise term of employee stock option grants. The Company has paid no dividends to stockholders. The risk-free interest rate is based on the zero-coupon U.S. Treasury yield at the date of grant for a term equivalent to the expected term of the option.
	Stock-based compensation expense includes stock options granted to employees and non-employees and has been reported in the Company’s statements of operations as follows:
		Three months Ended				Nine months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Research and development	$	751,509	$	154,760	$	2,538,636	$	246,011
	General and administrative	313,867		51,513		1,388,739		92,289
	Total	$	1,065,376	$	206,273	$	3,927,375	$	338,300
	The Company had 34,507 shares of restricted common stock granted to employees at December 31, 2012 and 255,394 shares of restricted common stock granted to employees at September 30, 2013. Of these shares, there were 34,507 and 227,513 unvested shares of restricted common stock at December 31, 2012 and September 30, 2013, respectively.

Net_Loss_Income_Per_Common_Sha

Net (Loss) Income Per Common Share	9 Months Ended
	Sep. 30, 2013
Net (Loss) Income Per Common Share	'
Net (Loss) Income Per Common Share	'
	3. Net (Loss) Income Per Common Share
	Basic and diluted net (loss) income per common share is determined by dividing net (loss) income applicable to common stockholders by the weighted average common shares outstanding during the period. For the periods where there is a net loss attributable to common stockholders, the convertible long term debt, unvested restricted shares and common stock options have been excluded from the calculation of diluted loss (income) per common stockholder because their effect would be anti-dilutive. Therefore, the weighted average shares used to calculate both basic and diluted loss per share would be the same.
	The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Basic and diluted net loss per common share calculation:
	Net loss	$	(5,573,524	)	$	(1,929,575	)	$	(16,529,808	)	$	(4,944,798	)
	Basic and diluted weighted-average common shares	12,471,472			3,441,995			9,520,179			3,441,995
	Basic and diluted net loss per share	$	(0.45	)	$	(0.56	)	$	(1.74	)	$	(1.44	)
	The following potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding for the periods presented, as they would be anti-dilutive:
		Nine Months Ended
		September 30
		2013		2012
	Unvested restricted stock	227,513		34,507
	Warrants	99,529		—
	Convertible Notes	—		233,967
	Options outstanding	1,484,315		1,819,839
	Total	1,811,357		2,088,313

Furniture_and_Fixtures

Furniture and Fixtures	9 Months Ended
	Sep. 30, 2013
Furniture and Fixtures	'
Furniture and Fixtures	'
	4. Furniture and Fixtures
	Furniture and fixtures consist of the following:
		September 30,			December 31,
		2013			2012
	Office furniture and fixtures	460,000			—
	Less accumulated depreciation	(38,333		)	—
	Furniture and fixtures, net	$	421,667		$	—
	Depreciation expense was $38,333 and $38,333 for the three months and the nine months ended September 30, 2013, respectively.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements	'
Fair Value Measurements	'
	5. Fair Value Measurements
	FASB Accounting Standards Codification (ASC) 820-10 “Fair Value Measurements and Disclosures” (ASC 820-10) provides a framework for measuring fair value under GAAP and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:
	Level 1 - Quoted prices in active markets for identical assets or liabilities. The Company’s Level 1 assets consist of money market investments.
	Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s Level 3 assets and liabilities consist of the put option liability associated with the issuance of the Company’s 2.45% Convertible Notes. The fair value of the put option liability was determined utilizing a probability weighted discounted financial model based on management’s assessment of the likelihood of achievement of certain outcomes.
	The following table sets forth the Company’s assets and liabilities that were measured at fair value on a recurring basis at September 30, 2013 and December 31, 2012 by level within the fair value hierarchy. As required by ASC 820-10, assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability:
	Assets and Liabilities	Quoted Prices In			Significant			Significant			Balance as of
		Active Markets			Other			Unobservable			30-Sep-13
		for Identical			Observable			Inputs
		Assets			Inputs			(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Cash and cash equivalents	$	87,667,229		$	—		$	—		$	87,667,229
	Total assets at fair value	$	87,667,229		$	—		$	—		$	87,667,229
	Liabilities:
	Put Option	$	—		$	—		$	—		$	—
	Total liabilities at fair value	$	—		$	—		$	—		$	—
	Assets and Liabilities	Quoted Prices In			Significant			Significant			Balance as of
		Active Markets			Other			Unobservable			31-Dec-12
		for Identical			Observable			Inputs
		Assets			Inputs			(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Cash and cash equivalents	$	2,025,338		$	—		$	—		$	2,025,338
	Total assets at fair value	$	2,025,338		$	—		$	—		$	2,025,338
	Liabilities:
	Put Option	$	—		$	—		$	(30,415	)	$	(30,415	)
	Total liabilities at fair value	$	—		$	—		$	(30,415	)	$	(30,415	)
	The Company measured the put option liability at fair value based on significant inputs not observable in the market, which causes it to be classified as a Level 3 measurement within the fair value hierarchy. The valuation of the put option liability uses assumptions and estimates the Company believes would be made by a market participant in making the same valuation. The Company assesses these assumptions and estimates on an on-going basis as additional data impacting the assumptions and estimates are obtained. Changes in the fair value of the put option liability related to updated assumptions and estimates are recognized within the statements of operations.
	Level 3 Disclosures
	The following table provides quantitative information associated with the fair value measurement of the Company’s Level 3 inputs:
		Fair Value as of			Valuation Technique		Unobservable Input		Range
		31-Dec-12							(Weighted Average)
	Put option liability	$	30,415		Probability-adjusted discounted cash flow		Probabilities of success		25% — 45%
									-35%
							Periods in which outcomes are expected to be achieved		2013
							Discount rate		12%
	The changes in fair value of the Company’s Level 3 put option liability during the nine months ended September 30, 2013 were as follows:
		Level 3
	Balance at December 31, 2012	$	30,415
	Fair value adjustment to put option liability included in other income	(30,415		)
	Balance as of September 30, 2013	$	—
	For the nine months ended September 30, 2013, the changes in the fair value of the put option liability resulted from the expiration of the put option in conjunction with the conversion of half of the principal of the 2.45% convertible note, along with accrued interest, into common stock as a result of the IPO.  The balance of the note was converted into common stock in April 2013. No other changes in valuation techniques or inputs occurred during the nine months ended September 30, 2013. No transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy occurred during the nine months ended September 30, 2013.

Accounts_Payable_and_Accrued_E

Accounts Payable and Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Accounts Payable and Accrued Expenses	'
Accounts Payable and Accrued Expenses	'
	6. Accounts Payable and Accrued Expenses
	Accounts payable and accrued expenses consist of the following:
		September 30,		December 31,
		2013		2012
	Accrued research and development costs	$	1,224,128	$	972,218
	Accrued compensation	1,035,896		100,000
	Accrued professional fees	400,967		4,024,234
	Other liabilities	190,262		404,283
	Total	$	2,851,253	$	5,500,735

Convertible_Notes

Convertible Notes	9 Months Ended
	Sep. 30, 2013
Convertible Notes	'
Convertible Notes	'
	7. Convertible Notes
	On March 16, 2010, in connection with the redemption of the Series A preferred stock, the Company issued a Senior Convertible Note (“the 2.45% Convertible Note”) in the amount of $1.25 million.  The 2.45% Convertible Note was initially recorded at fair value of $0.90 million. The 2.45% Convertible Note and the related interest expense were due on March 16, 2015. Interest is being charged at a rate of 2.45% per annum.
	Upon the occurrence of a qualified financing event as defined in the agreement, the 2.45% Convertible Note and any accrued interest were mandatorily convertible into shares of the same securities issued in the qualified financing at the same price per share used in the qualified financing.  In addition, upon the occurrence of a non-qualified financing event, as defined in the agreement, the 2.45% Convertible Note and any accrued interest were convertible at the option of the holder into cash or shares (the “Put Option”) of the same securities issued in the non-qualified financing event at the same price per share used in the non-qualified financing event, or the holder may elect to continue to retain the note.
	The Put Option was recorded at approximately $111,000, its fair value on the date of issuance and is marked to fair value at each reporting period.
	On July 26, 2012, the Company and NB Athyrium LLC, the holder of the 2.45% Convertible Note, entered into an amendment to the 2.45% Convertible Note pursuant to which NB Athyrium agreed to accelerate repayment of $625,000 in principal amount, plus accrued interest thereon, of such note in cash, at the time of the initial public offering, and convert the remaining $625,000 in principal amount, plus accrued interest thereon, into shares of our common stock at the initial public offering price.  On November 14, 2012, the Company and NB Athyrium LLC, entered into an additional amendment to the 2.45% Convertible Note pursuant to which NB Athyrium agreed to cancel the acceleration and defer the repayment of $625,000 in principal amount, plus accrued interest thereon, of such note in cash until February 28, 2014
	As a result of the successful completion of the IPO in January 2013, $625,000 in principal amount, plus accrued interest thereon, of the 2.45% Convertible Note converted into 66,913 shares of our common stock at the initial public offering price of $10.00 per share.  In April 2013, the Company and NB Athyrium LLC, the holder of the 2.45% Convertible Note, entered into an amendment to the 2.45% Convertible Notes pursuant to which NB Athyrium agreed to convert the remaining $625,000 in principal amount, plus accrued interest thereon, into 67,198 shares of our common stock at the initial public offering price of $10.00 per share.  As of September 30, 2013, all of the obligations under the 2.45% Convertible Note had been satisfied.
	In January 2012, the Company issued $0.9 million of convertible notes (the “1.27% Convertible Notes”) at face value for cash. As a result of the successful completion of the IPO in January 2013, the 1.27% Convertible Notes and related accrued interest were converted into 99,856 shares of our common stock at a conversion price equal to 87.5% of the initial public offering of $10.00 per share. A beneficial conversion charge of $125,000, the difference between the conversion price and the fair value of the new shares multiplied by the number of shares, was recorded to earnings with a corresponding credit to additional paid-in capital.
	During the three months ended September 30, 2013 and 2012, the Company recorded interest expense of approximately $0, and $18,999, respectively, related to the amortization of the debt discount.  During the nine months ended September 30, 2013 and 2012, the Company recorded interest expense of approximately $76,355 and $55,070, respectively, related to the amortization of the debt discount.

Stock_Option_Plan

Stock Option Plan	9 Months Ended
	Sep. 30, 2013
Stock Option Plan	'
Stock Option Plan	'
	8.  Stock Option Plan
	The Company’s 2012 Stock Equity Incentive Plan (the “2012 Plan”), which was adopted by the board of directors and approved by the stockholders in July 2012, became effective immediately prior to the closing of the Company’s initial public offering. In addition, the Company’s 2004 Stock Option and Grant Plan (the “2004 Plan”) was terminated effective immediately prior to the closing of the Company’s initial public offering. The 1,819,839 options to purchase common stock and 34,507 restricted stock awards executed prior to the effective date of such termination remain in full force and effect pursuant to their terms and the terms of the 2004 Plan. The 2012 Plan initially authorized the Company to grant up to 1,663,727 shares of common stock to eligible employees, directors, consultants and advisors to the Company in the form of options to purchase common stock in the Company at a price not less than the estimated fair value at the date of grant. Under the provisions of the 2012 Plan, no option will have a term in excess of 10 years.
	Subsequent to the closing of the IPO, certain options and restricted stock began to vest to directors, consultants and key employees. The Company recorded approximately $1.4 million of stock-based compensation expense associated with 573,424 options with a weighted average exercise price of $2.38 and 8,625 shares of restricted stock that fully vested upon consummation of an IPO. In addition, 281,895 options commenced vesting based upon the consummation of the IPO and the Company will record $1.8 million on the vesting of these options over their expected lives.
	The following is a summary of stock option activity under the 2012 and 2004 Plans through September 30, 2013:
		Options		Weighted-		Weighted-	Aggregate
				Average		Average	Intrinsic
				Exercise Price		Remaining	Value
						Contractual Life
	Outstanding at December 31, 2012	1,819,839		$	2.76
	Options granted	141,500		18.96
	Options exercised	(374,972	)	2.93
	Options expired	(43,324	)	1.98
	Options forfeited	(58,728	)	3.24
	Outstanding at September 30, 2013	1,484,315		$	4.27	6.45	$	60,901,220
	Options exercisable at September 30, 2013	956,174		$	3.02	5.3	$	40,417,268
	The following is a summary of restricted stock activity under the 2012 and 2004 Plans through September 30, 2013:
		Restricted Stock
	Outstanding at December 31, 2012	34,507
	Shares granted	231,614
	Shares cancelled	(6,745	)
	Shares forfeited	(3,982	)
	Outstanding at September 30, 2013	255,394
	Vested shares at September 30, 2013	27,881
	Total unrecognized compensation expense is $7.4 million, which will be recognized over a weighted average period of 1.5 years.

Common_Stock

Common Stock	9 Months Ended
	Sep. 30, 2013
Common Stock	'
Common Stock	'
	9. Common Stock
	At the 2013 annual meeting of stockholders held on June 19, 2013, the stockholders voted in favor of an amendment to the Company’s Restated Certificate of Incorporation to increase the Company’s authorized share capital by 11,250,000 shares of common stock.  As of September 30, 2013, the Company was authorized to issue 33,750,000 shares of common stock.
	Dividends on common stock will be paid when, and if, declared by the board of directors. Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. The Company will, at all times, reserve and keep available, out of its authorized but unissued shares of common stock, sufficient shares to effect the conversion of the shares of the stock options. As of September 30, 2013, the Company reserved 2,774,928 shares of common stock for future issuance related to the exercise of the Company’s outstanding stock options.
	Representative’s Warrants
	On October 1, 2012, the Company agreed to issue to the representative of the underwriters in the IPO warrants to purchase up to 99,529 shares of the Company’s common stock in the event of a successful public offering.  The warrants are exercisable for cash or on a cashless basis at a price per share equal to $15.00.  Based on a successful public offering in January these warrants were issued and accounted for as a cost of issuance.  The Company has determined, based upon a Black-Scholes model, that the fair value of the warrants on the date of IPO was $413,146.  The Company has accounted for the fair value of the warrants as a cost of issuance of common stock from the IPO resulting in a charge directly to stockholder’s equity.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies	'
Commitments and Contingencies	'
	10. Commitments and Contingencies
	License Agreements
	The Company has entered into research and development agreements with third parties for the development of oncology products. These agreements require the Company to fund the development of such products and potentially make milestone payments and royalties on net sales in the future based on the Company’s successful development of the products. The timing and the amount of milestone payments in the future are not certain.
	Under the Company’s license agreements, the Company could be required to pay up to a total of $29.0 million upon achieving certain milestones, such as the initiation of clinical trials or the granting of patents. From inception through September 30, 2013, the Company has paid or accrued $2.1 million in payments resulting from the execution of certain agreements, patent approvals, the initiation of sponsor research agreements, and compound development agreements. Milestone payments will also be due upon the issuance of certain patents, the initiation of certain clinical trials, the submission of regulatory applications and certain regulatory approvals, in addition to sales milestones and single digit royalties payable on commercial sales if any occur.
	Compensation Arrangements
	Subsequent to the closing of the IPO, certain bonuses and salary increases in the amount of $1.0 million were paid upon approval of the board of directors and the satisfaction of certain contingencies, with an additional $0.4 million subject to the same contingencies and payable one year after the IPO.
	Contractual Agreement
	In February 2013, the Company entered into a bioprocessing services agreement with a vendor for approximately $2.9 million if all services are performed under the contract. As of September 30, 2013 approximately $1.1 million of the contract had been paid or accrued.  Services under this contract are expected to be performed during 2013 and 2014.
	Lease Agreement
	In July 2013, the Company entered into a leasing agreement with respect to its corporate offices at 750 Lexington Avenue, New York, New York, for a monthly rent of $50,625.  The term of this lease agreement is 36 months.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions	'
Related Party Transactions	'
	11. Related Party Transactions
	Assignment Agreement with the Company’s Chief Executive Officer
	On June 15, 2012, the Company entered into an assignment agreement with Dr. Bergstein. Pursuant to the assignment agreement, as amended on November 7, 2012, effective as of January 28, 2013.  Dr. Bergstein assigned to the Company all of his right, title and interest in certain proprietary patent rights and related technology in exchange for $2.0 million in cash payable if the Company achieved a market capitalization of at least $200 million for a prescribed period, which it did in June 2013.  The Company accounted for this transaction as an asset acquisition because it did not acquire any processes or activities in addition to the assigned rights and technology. None of the assigned patent rights and related technology has alternative future uses, nor have they reached a stage of technological feasibility.  The Company recorded the entire $2.0 million amount to research and development expense. The assignment agreement does not contain any vesting or rescission/refund provisions.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events	'
Subsequent Events	'
	12. Subsequent Events
	The Company evaluated events that occurred subsequent to September 30, 2013 through the date the financial statements were available to be issued.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
Furniture and Fixtures	'
	Furniture and Fixtures
	Furniture and fixtures are stated at cost, less accumulated depreciation. Depreciation is provided over the estimated useful lives of the respective assets, which is three years, using the straight-line method.
Concentration of Credit Risk	'
	Concentration of Credit Risk
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents. The Company invests its excess cash principally in a 100% U.S. Treasury Money Market Fund and the remaining balances in a major U.S. bank, and its deposits, at times, exceed federally insured limits. The Company has not experienced any losses from credit risks.
Stock-Based Compensation	'
	Stock-Based Compensation
	The Company follows the provisions of the ASC Topic 718, Compensation — Stock Compensation which requires the measurement and recognition of compensation expense for all stock-based payment awards made to employees and non-employee directors, including employee stock options. Stock compensation expense based on the grant date fair value estimated in accordance with the provisions of ASC 718 is generally recognized as an expense over the requisite service period.
	The Company elected to recognize compensation cost using the straight-line attribution method for all service-based stock options.  For performance-based stock options share based compensation expense is recorded using the accelerated attribution method.
	For stock options granted as consideration for services rendered by non-employees, the Company recognizes expense in accordance with the requirements of ASC Topic 505-50, Equity Based Payments to Non-Employees. Non-employee option grants that do not vest immediately upon grant are recorded as an expense over the vesting period of the underlying stock options. At the end of each financial reporting period prior to vesting, the value of these options, as calculated using the Black-Scholes option-pricing model, will be re-measured using the fair value of the Company’s common stock and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair market value of options granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the stock options are fully vested.
	Prior to becoming a public company, the board of directors determined the estimated fair value of the Company’s common stock based on a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector and the prices at which the Company sold shares of its common stock.
	Due to the lack of trading history, the Company’s computation of stock-price volatility is based on the volatility rates of comparable publicly held companies over a period equal to the estimated useful life of the options granted by the Company. The Company’s computation of expected life was determined using the “simplified” method which is the midpoint between the vesting date and the end of the contractual term. The Company believes that it does not have sufficient reliable exercise data in order to justify the use of a method other than the “simplified” method of estimating the expected exercise term of employee stock option grants. The Company has paid no dividends to stockholders. The risk-free interest rate is based on the zero-coupon U.S. Treasury yield at the date of grant for a term equivalent to the expected term of the option.
	Stock-based compensation expense includes stock options granted to employees and non-employees and has been reported in the Company’s statements of operations as follows:
		Three months Ended				Nine months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Research and development	$	751,509	$	154,760	$	2,538,636	$	246,011
	General and administrative	313,867		51,513		1,388,739		92,289
	Total	$	1,065,376	$	206,273	$	3,927,375	$	338,300
	The Company had 34,507 shares of restricted common stock granted to employees at December 31, 2012 and 255,394 shares of restricted common stock granted to employees at September 30, 2013. Of these shares, there were 34,507 and 227,513 unvested shares of restricted common stock at December 31, 2012 and September 30, 2013, respectively.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
Schedule of stock-based compensation expense including stock options granted to employees and non-employees	'
		Three months Ended				Nine months Ended
		September 30,				September 30,
		2013		2012		2013		2012
	Research and development	$	751,509	$	154,760	$	2,538,636	$	246,011
	General and administrative	313,867		51,513		1,388,739		92,289
	Total	$	1,065,376	$	206,273	$	3,927,375	$	338,300

Net_Loss_Income_Per_Common_Sha1

Net (Loss) Income Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2013
Net (Loss) Income Per Common Share	'
Schedule of computation of basic and diluted net loss per share	'
		Three Months Ended September 30,						Nine Months Ended September 30,
		2013			2012			2013			2012
	Basic and diluted net loss per common share calculation:
	Net loss	$	(5,573,524	)	$	(1,929,575	)	$	(16,529,808	)	$	(4,944,798	)
	Basic and diluted weighted-average common shares	12,471,472			3,441,995			9,520,179			3,441,995
	Basic and diluted net loss per share	$	(0.45	)	$	(0.56	)	$	(1.74	)	$	(1.44	)
Schedule of potentially dilutive securities that have been excluded from the computations of diluted weighted average shares outstanding	'
		Nine Months Ended
		September 30
		2013		2012
	Unvested restricted stock	227,513		34,507
	Warrants	99,529		—
	Convertible Notes	—		233,967
	Options outstanding	1,484,315		1,819,839
	Total	1,811,357		2,088,313

Furniture_and_Fixtures_Tables

Furniture and Fixtures (Tables)	9 Months Ended
	Sep. 30, 2013
Furniture and Fixtures	'
Schedule of furniture and fixtures	'
		September 30,			December 31,
		2013			2012
	Office furniture and fixtures	460,000			—
	Less accumulated depreciation	(38,333		)	—
	Furniture and fixtures, net	$	421,667		$	—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements	'
Schedule of assets and liabilities measured at fair value on recurring basis	'
	Assets and Liabilities	Quoted Prices In			Significant			Significant			Balance as of
		Active Markets			Other			Unobservable			30-Sep-13
		for Identical			Observable			Inputs
		Assets			Inputs			(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Cash and cash equivalents	$	87,667,229		$	—		$	—		$	87,667,229
	Total assets at fair value	$	87,667,229		$	—		$	—		$	87,667,229
	Liabilities:
	Put Option	$	—		$	—		$	—		$	—
	Total liabilities at fair value	$	—		$	—		$	—		$	—
	Assets and Liabilities	Quoted Prices In			Significant			Significant			Balance as of
		Active Markets			Other			Unobservable			31-Dec-12
		for Identical			Observable			Inputs
		Assets			Inputs			(Level 3)
		(Level 1)			(Level 2)
	Assets:
	Cash and cash equivalents	$	2,025,338		$	—		$	—		$	2,025,338
	Total assets at fair value	$	2,025,338		$	—		$	—		$	2,025,338
	Liabilities:
	Put Option	$	—		$	—		$	(30,415	)	$	(30,415	)
	Total liabilities at fair value	$	—		$	—		$	(30,415	)	$	(30,415	)
Schedule of quantitative information associated with fair value measurement of the Company's Level 3 inputs	'
		Fair Value as of			Valuation Technique		Unobservable Input		Range
		31-Dec-12							(Weighted Average)
	Put option liability	$	30,415		Probability-adjusted discounted cash flow		Probabilities of success		25% — 45%
									-35%
							Periods in which outcomes are expected to be achieved		2013
							Discount rate		12%
Schedule of changes in fair value of the Company's Level 3 put option liability	'
		Level 3
	Balance at December 31, 2012	$	30,415
	Fair value adjustment to put option liability included in other income	(30,415		)
	Balance as of September 30, 2013	$	—

Accounts_Payable_and_Accrued_E1

Accounts Payable and Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Accounts Payable and Accrued Expenses	'
Schedule of components of accounts payable and accrued expenses	'
		September 30,		December 31,
		2013		2012
	Accrued research and development costs	$	1,224,128	$	972,218
	Accrued compensation	1,035,896		100,000
	Accrued professional fees	400,967		4,024,234
	Other liabilities	190,262		404,283
	Total	$	2,851,253	$	5,500,735

Stock_Option_Plan_Tables

Stock Option Plan (Tables)	9 Months Ended
	Sep. 30, 2013
Stock Option Plan	'
Summary of stock option activity	'
		Options		Weighted-		Weighted-	Aggregate
				Average		Average	Intrinsic
				Exercise Price		Remaining	Value
						Contractual Life
	Outstanding at December 31, 2012	1,819,839		$	2.76
	Options granted	141,500		18.96
	Options exercised	(374,972	)	2.93
	Options expired	(43,324	)	1.98
	Options forfeited	(58,728	)	3.24
	Outstanding at September 30, 2013	1,484,315		$	4.27	6.45	$	60,901,220
	Options exercisable at September 30, 2013	956,174		$	3.02	5.3	$	40,417,268
Summary of restricted stock activity	'
		Restricted Stock
	Outstanding at December 31, 2012	34,507
	Shares granted	231,614
	Shares cancelled	(6,745	)
	Shares forfeited	(3,982	)
	Outstanding at September 30, 2013	255,394
	Vested shares at September 30, 2013	27,881

Organization_and_Basis_of_Pres1

Organization and Basis of Presentation (Details) (USD $)	0 Months Ended					9 Months Ended	122 Months Ended
	22-May-13	22-May-13	16-May-13	Jan. 31, 2013	Jan. 29, 2013	Sep. 30, 2013	Sep. 30, 2013
Organization and Basis of Presentation	'	'	'	'	'	'	'
Number of shares issued in initial public offering or in secondary public offering	'	'	4,137,931	3,317,644	'	'	'
Share price (in dollars per share)	$14.50	'	$14.50	$10	$10	'	'
Number of shares issued pursuant to an option granted to the underwriters to cover over-allotments	620,689	'	'	'	497,647	'	'
Aggregate gross proceeds from initial public offering	'	'	'	$38,200,000	'	'	'
Aggregate gross proceeds from secondary public offering	'	69,000,000	'	'	'	'	'
Proceeds from secondary public offering net of underwriting fees and offering expenses	'	64,500,000	'	'	'	97,708,506	101,550,788
Net proceeds received after underwriting fees and offering expenses	'	'	'	32,300,000	'	'	'
Number of shares of common stock issued upon conversion of debt	'	'	'	166,769	'	'	'
Principal amount of convertible debt converted	'	'	'	1,400,000	'	'	'
Compensation expense related to certain bonuses and salary increases payable upon continued employment and the occurrence of a specified financing	'	'	'	1,500,000	'	'	'
Stock-based compensation expense for awards that fully vested upon consummation of IPO (in dollars)	'	'	'	$1,400,000	'	'	'

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Furniture and Fixtures	'	'	'	'
Estimated useful lives	'	'	'P3Y	'
Dividends paid to stockholders	'	'	$0	'
Stock-Based Compensation	'	'	'	'
Stock-based compensation expense	1,065,376	206,273	3,927,375	338,300
Research and development	'	'	'	'
Stock-Based Compensation	'	'	'	'
Stock-based compensation expense	751,509	154,760	2,538,636	246,011
General and administrative	'	'	'	'
Stock-Based Compensation	'	'	'	'
Stock-based compensation expense	$313,867	$51,513	$1,388,739	$92,289

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 2) (Restricted stock)	Sep. 30, 2013	Dec. 31, 2012
Restricted stock	'	'
Stock-Based Compensation	'	'
Number of restricted common stock granted to employees (in shares)	255,394	34,507
Number of unvested restricted common stock granted to employees (in shares)	227,513	34,507

Net_Loss_Income_Per_Common_Sha2

Net (Loss) Income Per Common Share (Details) (USD $)	3 Months Ended		9 Months Ended		122 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Basic and diluted net loss per common share calculation:	'	'	'	'	'
Net loss (in dollars)	($5,573,524)	($1,929,575)	($16,529,808)	($4,944,798)	($26,290,226)
Basic and diluted weighted average common shares	12,471,472	3,441,995	9,520,179	3,441,995	'
Basic and diluted net loss per share (in dollars per share)	($0.45)	($0.56)	($1.74)	($1.44)	'

Net_Loss_Income_Per_Common_Sha3

Net (Loss) Income Per Common Share (Details 2)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Net (Loss) Income Per Common Share	'	'
Potentially dilutive securities excluded from the computation of earnings per share (in shares)	1,811,357	2,088,313
Unvested restricted stock	'	'
Net (Loss) Income Per Common Share	'	'
Potentially dilutive securities excluded from the computation of earnings per share (in shares)	227,513	34,507
Warrants	'	'
Net (Loss) Income Per Common Share	'	'
Potentially dilutive securities excluded from the computation of earnings per share (in shares)	99,529	'
Convertible Notes	'	'
Net (Loss) Income Per Common Share	'	'
Potentially dilutive securities excluded from the computation of earnings per share (in shares)	'	233,967
Options outstanding	'	'
Net (Loss) Income Per Common Share	'	'
Potentially dilutive securities excluded from the computation of earnings per share (in shares)	1,484,315	1,819,839

Furniture_and_Fixtures_Details

Furniture and Fixtures (Details) (USD $)	3 Months Ended	9 Months Ended	122 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2013
Furniture and fixtures	'	'	'
Less accumulated depreciation	($38,333)	($38,333)	($38,333)
Furniture and fixtures, net	421,667	421,667	421,667
Depreciation expense	38,333	38,333	38,333
Office furniture and fixtures	'	'	'
Furniture and fixtures	'	'	'
Office furniture and fixtures, Gross	$460,000	$460,000	$460,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2013	Mar. 16, 2010	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2012	Sep. 30, 2013	Dec. 31, 2012
		2.45% Convertible Notes	Recurring basis	Recurring basis	Recurring basis	Recurring basis	Recurring basis
			Quoted Prices In Active Markets for Identical Assets (Level 1)	Quoted Prices In Active Markets for Identical Assets (Level 1)	Significant Unobservable Inputs (Level 3)	Balance	Balance
Fair Value Measurements	'	'	'	'	'	'	'
Interest rate (as a percent)	'	2.45%	'	'	'	'	'
Assets:	'	'	'	'	'	'	'
Cash and cash equivalents	'	'	$87,667,229	$2,025,338	'	$87,667,229	$2,025,338
Total assets at fair value	'	'	87,667,229	2,025,338	'	87,667,229	2,025,338
Liabilities:	'	'	'	'	'	'	'
Put Option	'	'	'	'	-30,415	'	-30,415
Total liabilities at fair value	'	'	'	'	-30,415	'	-30,415
Transfers of assets between Level 1 to Level 2	0	'	'	'	'	'	'
Transfers of assets between Level 2 to Level 1	$0	'	'	'	'	'	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 2) (Recurring basis, Level 3, USD $)	12 Months Ended
	Dec. 31, 2012
Fair Value Measurements	'
Put option liability	30,415
Put option liability	'
Fair Value Measurements	'
Put option liability	30,415
Put option liability | Probability-adjusted discounted cash flow	'
Fair Value Measurements	'
Discount rate (as a percent)	12.00%
Put option liability | Probability-adjusted discounted cash flow | Minimum	'
Fair Value Measurements	'
Probabilities of success (as a percent)	25.00%
Put option liability | Probability-adjusted discounted cash flow | Maximum	'
Fair Value Measurements	'
Probabilities of success (as a percent)	45.00%
Put option liability | Probability-adjusted discounted cash flow | Weighted Average	'
Fair Value Measurements	'
Probabilities of success (as a percent)	35.00%

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 3) (Put option liability, USD $)	9 Months Ended
	Sep. 30, 2013
Put option liability	'
Changes in fair value of Level 3 put option liability	'
Balance at the beginning of the period	$30,415
Fair value adjustments included in other income	($30,415)

Accounts_Payable_and_Accrued_E2

Accounts Payable and Accrued Expenses (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accrued Liabilities	'	'
Accrued research and development costs	$1,224,128	$972,218
Accrued compensation	1,035,896	100,000
Accrued professional fees	400,967	4,024,234
Other liabilities	190,262	404,283
Total	$2,851,253	$5,500,735

Convertible_Notes_Details

Convertible Notes (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

22-May-13

16-May-13

Jan. 31, 2013

Jan. 29, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jan. 31, 2013

Jul. 26, 2012

Apr. 30, 2013

Nov. 14, 2012

Mar. 16, 2010

Mar. 16, 2010

Jan. 31, 2013

Jan. 31, 2012

2.45% Convertible Notes

2.45% Convertible Notes

2.45% Convertible Notes

2.45% Convertible Notes

2.45% Convertible Notes

2.45% Convertible Notes

1.27% Convertible Notes

1.27% Convertible Notes

Put Option

Convertible Notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt issued

'

'

'

'

'

'

'

'

'

'

'

'

$1,250,000

'

'

$900,000

Interest rate (as a percent)

'

'

'

'

'

'

'

'

'

'

'

'

2.45%

'

'

1.27%

Fair value of Convertible Note

'

'

'

'

'

'

'

'

'

'

'

'

900,000

'

'

'

Put option liability

'

'

'

'

'

'

'

'

'

'

'

'

'

111,000

'

'

Accelerated repayment of notes in cash at the time of initial public offering

'

'

'

'

'

'

'

'

'

625,000

'

'

'

'

'

'

Amount of debt to be converted at the time of the initial public offering

'

'

'

'

'

'

'

'

'

625,000

'

'

'

'

'

'

Number of shares of common stock issued upon conversion of debt

'

'

166,769

'

'

'

'

'

66,913

'

67,198

'

'

'

99,856

'

Amount of deferred repayment

'

'

'

'

'

'

'

'

'

'

'

625,000

'

'

'

'

Principal amount of convertible debt

'

'

1,400,000

'

'

'

'

'

625,000

'

625,000

'

'

'

'

'

Share price (in dollars per share)

$14.50

$14.50

$10

$10

'

'

'

'

$10

'

$10

'

'

'

$10

'

Beneficial conversion charge

'

'

'

'

'

'

'

'

'

'

'

'

'

'

125,000

'

Conversion price as a percentage of IPO price per share

'

'

'

'

'

'

'

'

'

'

'

'

'

'

87.50%

'

Interest expenses related to amortization of debt discount

'

'

'

'

$0

$18,999

$76,355

$55,070

'

'

'

'

'

'

'

'

Stock_Option_Plan_Details

Stock Option Plan (Details) (USD $)	0 Months Ended	9 Months Ended	0 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended		9 Months Ended
	Jan. 31, 2013	Sep. 30, 2013	Jan. 31, 2013	Sep. 30, 2013	Jan. 31, 2013	Sep. 30, 2013	Jan. 31, 2013	Sep. 30, 2013	Jan. 31, 2013	Jan. 31, 2013
			Options	Options	Restricted stock	Restricted stock	2012 Plan	2012 Plan	2004 Plan	2004 Plan
								Options	Options	Restricted stock
								Maximum
Stock Option Plan	'	'	'	'	'	'	'	'	'	'
Number of shares of common stock initially authorized for grant	'	'	'	'	'	'	1,663,727	'	'	'
Term of option	'	'	'	'	'	'	'	'10 years	'	'
Stock-based compensation expense	$1,400,000	'	'	'	'	'	'	'	'	'
Options that vested upon consummation of IPO (in shares)	'	'	573,424	'	'	'	'	'	'	'
Weighted average exercise price (in dollars per share)	'	'	$2.38	'	'	'	'	'	'	'
Restricted stock that fully vested upon consummation of IPO (in shares)	'	'	'	'	8,625	'	'	'	'	'
Options that commence vesting upon the occurrence of an IPO or a specified financing (in shares)	'	'	281,895	'	'	'	'	'	'	'
Expected stock-based compensation expense on vesting of options (in dollars)	'	7,400,000	1,800,000	'	'	'	'	'	'	'
Options	'	'	'	'	'	'	'	'	'	'
Outstanding balance at the beginning of the period (in shares)	'	'	'	1,819,839	'	'	'	'	1,819,839	'
Option Granted (in shares)	'	'	'	141,500	'	'	'	'	'	'
Options exercised (in shares)	'	'	'	-374,972	'	'	'	'	'	'
Options expired (in shares)	'	'	'	-43,324	'	'	'	'	'	'
Options forfeited (in shares)	'	'	'	-58,728	'	'	'	'	'	'
Outstanding balance at the end of the period (in shares)	'	'	'	1,484,315	'	'	'	'	1,819,839	'
Options exercisable (in shares)	'	'	'	956,174	'	'	'	'	'	'
Weighted Average Exercise Price	'	'	'	'	'	'	'	'	'	'
Outstanding balance at the beginning of the period (in dollars per share)	'	'	'	$2.76	'	'	'	'	'	'
Option Granted (in dollar per shares)	'	'	'	$18.96	'	'	'	'	'	'
Options exercised (in dollars per share)	'	'	'	$2.93	'	'	'	'	'	'
Options expired (in dollars per share)	'	'	'	$1.98	'	'	'	'	'	'
Options forfeited (in dollars per share)	'	'	'	$3.24	'	'	'	'	'	'
Outstanding balance at the end of the period (in dollars per share)	'	'	'	$4.27	'	'	'	'	'	'
Options exercisable (in dollars per share)	'	'	'	$3.02	'	'	'	'	'	'
Weighted-Average Remaining Contractual Life	'	'	'	'	'	'	'	'	'	'
Outstanding balance at the end of the period	'	'	'	'6 years 5 months 12 days	'	'	'	'	'	'
Options exercisable	'	'	'	'5 years 3 months 18 days	'	'	'	'	'	'
Aggregate Intrinsic Value	'	'	'	'	'	'	'	'	'	'
Outstanding balance at the end of the period (in dollars)	'	'	'	60,901,220	'	'	'	'	'	'
Options exercisable (in dollars)	'	'	'	$40,417,268	'	'	'	'	'	'
Restricted Stock	'	'	'	'	'	'	'	'	'	'
Outstanding balance at the beginning of the period (in shares)	'	'	'	'	34,507	34,507	'	'	'	34,507
Shares granted	'	'	'	'	'	231,614	'	'	'	'
Shares cancelled	'	'	'	'	'	-6,745	'	'	'	'
Shares forfeited	'	'	'	'	'	-3,982	'	'	'	'
Outstanding balance at the end of the period (in shares)	'	'	'	'	'	255,394	'	'	'	34,507
Vested shares	'	'	'	'	'	27,881	'	'	'	'
Weighted average period recognized	'	'1 year 6 months	'	'	'	'	'	'	'	'

Common_Stock_Details

Common Stock (Details) (USD $)	0 Months Ended		9 Months Ended
	Jun. 19, 2013	Jan. 31, 2013	Sep. 30, 2013	Dec. 31, 2012
			item
Common Stock	'	'	'	'
Additional shares of common stock authorized	11,250,000	'	'	'
Number of shares of common stock authorized to be issued	'	'	33,750,000	22,500,000
Number of votes to which holders of common shares are entitled for each share held	'	'	1	'
Number of shares of common stock reserved for future issuance related to the exercise of the Company's outstanding stock options	'	'	2,774,928	'
Number of shares of common stock that may be purchased by warrants	'	99,529	'	'
Exercisable price of warrants (in dollars per share)	'	$15	'	'
Fair value of warrants	'	$413,146	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	0 Months Ended	1 Months Ended	9 Months Ended
	Jan. 31, 2013	Jul. 31, 2013	Sep. 30, 2013	Sep. 30, 2013	Feb. 28, 2013
			Research and development agreements with third parties	Bioprocessing services agreement	Bioprocessing services agreement
License Agreements	'	'	'	'	'
Amount required to be paid upon achievement of certain milestones	'	'	$29,000,000	'	'
Amount paid or accrued	'	'	2,100,000	1,100,000	'
Contractual Agreement	'	'	'	'	'
Contractual agreement value	'	'	'	'	2,900,000
Compensation Arrangements	'	'	'	'	'
Bonuses and salary increases paid upon the closing of the IPO	1,000,000	'	'	'	'
Bonuses and salary increases payable upon the closing of the IPO	400,000	'	'	'	'
Period after IPO after which increased bonus and salary is paid	'1 year	'	'	'	'
Lease Agreement	'	'	'	'	'
Monthly rent expense	'	$50,625	'	'	'
Lease agreement term	'	'36 months	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended		9 Months Ended		122 Months Ended	0 Months Ended	1 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jun. 15, 2012	Jun. 30, 2013
						Dr. Bergstein	Dr. Bergstein
Related Party Transactions	'	'	'	'	'	'	'
Value of proprietary patent rights and related technology	'	'	'	'	'	$2,000,000	'
Minimum market capitalization	'	'	'	'	'	200,000,000	'
Amount recorded to acquired in-process research and development expense	$3,323,662	$1,221,290	$10,569,909	$2,834,630	$22,015,577	'	$2,000,000